Is a spinal cord stimulator right for CRPS?

Whether a spinal cord stimulator suits a person with complex regional pain syndrome is a decision for that person and a pain physician. The main randomized trial, Kemler 2000, found less pain at six months and no gain in function. By five years the pain result matched physical therapy alone. Revisions and removals of the device are common.

A painted apothecary bottle and mortar with a poppy and lupine.

What is a spinal cord stimulator?

A spinal cord stimulator is an implanted device that delivers small electrical pulses to the spinal cord through wires called leads. The 2022 practical guidelines in Pain Medicine describe conventional spinal cord stimulation as acting on pain pathways "at the level of the dorsal column of the spinal cord." The same guidelines state that spinal cord stimulation is an FDA-approved treatment for chronic pain that was first marketed in 1967.

Implantation happens in two steps. A patient first has a temporary trial of stimulation, and a permanent spinal cord stimulator is implanted only if the trial reduces pain. In the Kemler randomized trial, 24 of 36 patients passed the trial stage and received an implant.

What did the Kemler randomized trial find at six months?

The Kemler trial found that spinal cord stimulation reduced pain at six months and did not improve function. Kemler and colleagues reported the trial in The New England Journal of Medicine in 2000. They enrolled 54 Dutch patients who had reflex sympathetic dystrophy, the former name of CRPS type I, for at least six months. Thirty-six patients were assigned to spinal cord stimulation plus physical therapy and 18 to physical therapy alone.

At six months, pain in the stimulation group had fallen by a mean of 2.4 cm on a 10 cm scale, and pain in the physical therapy group had risen by 0.2 cm. Thirty-nine percent of the stimulation group rated themselves "much improved," compared with 6 percent of the control group. The authors wrote that "there was no clinically important improvement in functional status." Six of the 24 implanted patients had complications that required further procedures.

What happened to the Kemler trial patients after five years?

After five years, the pain benefit of spinal cord stimulation in the Kemler trial was no longer statistically distinguishable from physical therapy alone. The five-year report, published in the Journal of Neurosurgery in 2008, states that spinal cord stimulation plus physical therapy "produced results similar to those following" physical therapy "for pain relief and all other measured variables." Ten patients were excluded from the final analysis.

The same report records how patients judged the treatment. The authors wrote that "despite the diminishing effectiveness of SCS over time, 95% of patients with an implant would repeat the treatment for the same result." The Royal College of Physicians' 2018 guideline cites the Kemler follow-up for its statement that "the efficacy of spinal cord stimulation generally declines over time."

How do the studies of spinal cord stimulation compare?

One randomized trial against physical therapy and several follow-up series make up most of the evidence on spinal cord stimulation in CRPS.

Studies of spinal cord stimulation that included people with CRPS
StudyWho was studiedWhat it found
Kemler 2000 and 200854 patients with CRPS type I, randomizedLess pain at six months, no gain in function; similar to physical therapy alone at five years
Geurts 201384 implanted CRPS patients, up to 12 years41 percent had at least 30 percent pain relief; 63 percent still used the device
Hoikkanen 202127 implanted CRPS patients, median 8 years30 percent of devices removed; 63 percent of patients had a revision
Mekhail 2011707 stimulator cases, 345 for CRPSHardware complications in 38 percent; infection in 4.5 percent
Dhruva 20237,560 matched insurance patients, several diagnosesNo reduction in opioid use at two years; 22.1 percent revised or removed

How often do spinal cord stimulators need revision or removal?

Published series report that between about one in five and two in three patients with a spinal cord stimulator have a further procedure, depending on the length of follow-up. In the 2023 claims study by Dhruva and colleagues, 22.1 percent of 1,260 stimulator patients had a revision or removal within two years. At one academic center, Hayek and colleagues reported revision and removal rates of 23.9 percent each, and loss of effect was the most common reason for removal.

Longer follow-up shows more procedures. In the Finnish CRPS series by Hoikkanen and colleagues, 63 percent of implanted patients had a complication that led to revision over a median of eight years. In the Dutch cohort by Geurts and colleagues, 51 of 84 patients had 122 repeat procedures over 12 years, and 44 of those were battery changes.

Does a spinal cord stimulator reduce opioid use or restore function?

The published studies do not show that a spinal cord stimulator reduces opioid use or restores function in CRPS. The Kemler trial found no clinically important improvement in function at six months. A 2017 review by Visnjevac and colleagues rated the evidence for pain relief and quality of life as high level and called the evidence for functional improvement inconclusive.

In the Finnish CRPS series, none of the 6 patients using strong opioids stopped using them during two years of follow-up. The 2023 claims study by Dhruva and colleagues, which covered several chronic pain diagnoses, concluded that stimulator placement "was not associated with a reduction in opioid use or nonpharmacologic pain interventions at 2 years."

What do the guidelines say about spinal cord stimulation for CRPS?

The guidelines place spinal cord stimulation after rehabilitation-based care has not worked. The Royal College of Physicians' 2018 guideline states that neuromodulation "should be considered in patients with CRPS who have not responded to appropriate integrated management, including pain physiotherapy." The 2022 practical guidelines say that failure to progress in interdisciplinary care "may warrant consideration" of spinal cord stimulation.

The 2022 practical guidelines also state the limit of the research: "there is evidence supporting SCS and DRG for the treatment of CRPS, but high-quality and corroboratory evidence is needed." The 2023 Cochrane overview by Ferraro and colleagues "found no high-certainty evidence for any comparison" among CRPS treatments.

What has been reported to FDA about implanted pain stimulators?

FDA collects adverse event reports about medical devices, including implanted pain stimulators, and publishes them through its openFDA service. The tables below count the reports FDA holds under three device product codes: LGW and GZB for spinal cord stimulators and PMP for dorsal root ganglion stimulators. The counts cover stimulators implanted for any condition, not for CRPS alone.

Adverse event reports FDA received for spinal cord and dorsal root ganglion stimulators, by year
Year receivedReports
20109,419
201111,603
201219,004
201326,861
201422,099
201519,196
201620,484
201725,264
201831,006
201933,230
202030,895
202126,969
202225,436
202335,587
202437,470
202533,747
2026 (to date)28,410
What the 2025 reports described
Report typeReports
Injury27,179
Malfunction6,537
Death28
Other3

Source: openFDA device adverse event (MAUDE) and recall data, U.S. Food and Drug Administration. Retrieved . Report counts, not rates. FDA: adverse event reports are unverified, may be duplicated, and do not establish that a device caused the event. FDA does not publish how many devices were implanted. Most stimulators are implanted for conditions other than CRPS.

Why are FDA report counts not rates?

An FDA report count is not a rate because the count has no denominator. FDA does not publish how many spinal cord stimulators were implanted in a given year, so the number of reports cannot be divided by the number of devices in use. A rising count can reflect more implants, more reporting, or more problems, and the reports alone cannot separate the three.

The reports are also unverified. One event can be reported more than once, and a report does not establish that the device caused the event. The openFDA service attaches a disclaimer to every result: "you should assume all results are unvalidated." Complication rates come from studies that follow a known number of patients, such as the Dhruva, Hayek and Geurts studies described on this page.

Which stimulator recalls has FDA listed?

FDA lists recalls of spinal cord and dorsal root ganglion stimulator components in the same openFDA service, and the ten newest are shown below. A recall on the list can concern programming software, an accessory or the implanted hardware. The reason FDA records for each recall is quoted as FDA lists it. A person with an implanted stimulator can ask the implanting physician whether a listed recall applies to the model implanted.

  1. Boston Scientific Neuromodulation Corporation, recall started September 30, 2026 (Open, Classified)Product: Nalu TD2 Therapy Disc with firmware, REF: 34014-001, and TD2 Patient Kit, REF: 74011, part of the Nalu Neurostimulation SystemReason FDA lists: Therapy Disc (TD) that powers and sends stimulation signals to an Implantable Pulse Generator (IPG), part of a neurostimulation system, has a firmware issue that causes the TD to attempt to restart, then fail, leading it to become non-functional, and if a secondary TD is unavailable, this may lead IPG to become non-functional, thus unable to inhibit transmission of pain signals.
  2. Boston Scientific Neuromodulation Corporation, recall started June 17, 2026 (Open, Classified)Product: INFINION CX LEAD KIT, 50CM, Model: SC-2317-50, Material: M365SC2317500; INFINION CX LEAD KIT, 70CM, Model: SC-2317-70, Material: M365SC2317700. part of the Boston Scientific Spinal Cord Stimulator (SCS) Systems.Reason FDA lists: Spinal cord stimulation system lead body may be exposed to stress at the anchor site. This may result in high impedance measurements or lead fractures, which may lead to inadequate stimulation, additional intervention, including lead explant and replacement.
  3. Boston Scientific Neuromodulation Corporation, recall started April 29, 2026 (Open, Classified)Product: Boston Scientific Model SC-4318, Clik X Anchor REF: M365SC43180Reason FDA lists: Sterile anchors my lack sterility assurance.
  4. Medtronic Neuromodulation, recall started December 3, 2025 (Open, Classified)Product: A71200 Vanta" Clinician Programmer Application (CP App) version 2.0.2465 and 2.0.2683, Product number A71200. Software is deployed and operated on Samsung tablets (CFN CT900).Reason FDA lists: Complaints received that Vanta A71200 CP App does not function as intended during use. There is a potential for prolonged or postponed surgical procedure.
  5. Medtronic Neuromodulation, recall started November 20, 2025 (Open, Classified)Product: Restore Clinician Programmer Application (CP App), Model A71100 used with the following programmers: CT900A PROG CT900A CLINICIAN TABLET US CT900B PROG CT900B CLINICIAN TABLET EU -UK CT900C PROG CT900C CLINICIAN TABLET Reason FDA lists: Software issue where a Device Reset message displayed on the app was unable to be cleared. In rare cases, this resulted in an inability to resume therapy, and the patient experienced a recurrence of underlying pain symptoms. Resolution would require surgical replacement of the INS.
  6. Abbott Medical, recall started October 6, 2025 (Open, Classified)Product: Eterna SCS IPG (Implantable Pulse Generator), Model Number 32400Reason FDA lists: There is a potential issue affecting Eterna Spinal Cord Stimulation (SCS) Implantable Pulse Generators (IPGs), Model 32400 and Liberta RC Deep Brain Stimulation (DBS) Implantable Pulse Generators (IPGs), Model 62400 . These devicess may experience a loss of communication with the Clinician Programmer (CP) and/or the Patient Controller (PC).
  7. Medtronic Neuromodulation, recall started March 4, 2025 (Open, Classified)Product: Stimulation RC Clinician Programmer Application, Model A71400, when used with the Inceptiv (Model 977119) and Intellis Pro (Model 977118) neurostimulatorsReason FDA lists: There is a software issue that can permanently disable communication with an implantable neurostimulator (INS) when a specific intraoperative programming sequence is used.
  8. Medtronic Neuromodulation, recall started September 18, 2024 (Open, Classified)Product: Medtronic Recharger Kits, RS6230, RS7230, and RS5220A, containing components WR9230 and WR9220A Recharger for rechargeable implantable neurostimulators. The Rechargers are used with Neurostimulator Inceptiv INS Model 97Reason FDA lists: The Wireless Rechargers in the kits may be unable to enter a recharging session upon first use.
  9. Medtronic Neuromodulation, recall started August 21, 2024 (Open, Classified)Product: Vanta Implantable Neurostimulator (INS), Model 977006Reason FDA lists: Model 977006 Vanta INS batterty life has depleted faster than HCPs or patients expected leading to outpatient reprogramming or earlier than anticipated surgical replacements.
  10. Boston Scientific Neuromodulation Corporation, recall started July 17, 2024 (Open, Classified)Product: WAVEWRITER ALPHA: Model: SC-1216, 16 IPG KIT, REF: M365SC12160; Model: SC-1232, 32 IPG KIT, REF: M365SC12320Reason FDA lists: Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) may experience routine system check during IPG charging, which may cause device reset, which may lead to transient loss of stimulation; patients may experience undesired sensations when therapy turns off for approx. 10-15 seconds and then back on, which may lead patient to request surgical intervention for replacement or revision.

Source: openFDA device adverse event (MAUDE) and recall data, U.S. Food and Drug Administration. Retrieved . FDA lists 104 recalls under these product codes in all; the ten newest are shown.

What does spinal cord stimulation cost?

Cost studies of spinal cord stimulation disagree, and they measure different health systems. Kemler and Furnee's 2002 economic evaluation of the Dutch trial found that stimulation cost $4,000 more per patient than control therapy in the first year and projected that it would cost $60,000 less over a lifetime. The lifetime figure was a projection.

The 2023 United States claims study by Dhruva and colleagues reported that "total costs of care in the first year were $39 000 higher" with a spinal cord stimulator than with conventional medical management, and similar in the second year. Repeat procedures add to long-term cost. In a claim for future medical care, the projected cost of battery changes and revisions is set out in a life care plan.

Is spinal cord stimulation for CRPS being studied in California?

Yes. Scripps Health in La Jolla is running a study of closed-loop spinal cord stimulation for CRPS, registered as NCT06421350. The registry lists a planned enrollment of 32 adults with CRPS type I or type II in one limb who have never had neuromodulation. The study compares the response when the device is used in the early phases of CRPS with the response in the chronic phase. The registry listed the study as recruiting when this page was checked, and a listing is not a recommendation. The CRPS clinical trial finder shows current status.

Common questions

Results vary by patient, and the average benefit declines. In the Kemler randomized trial, pain relief at six months was no longer different from physical therapy alone at five years. In a Dutch cohort of 84 implanted patients reported by Geurts and colleagues in 2013, 41 percent had at least 30 percent pain relief at the end point, and 63 percent still used the device during 12 years of follow-up.

A trial is a short test of stimulation before any permanent implant. In the Kemler study, a permanent stimulator was implanted only if test stimulation succeeded, and 24 of 36 patients went on to an implant. At the Cleveland Clinic, Mekhail and colleagues reported that 75 percent of trials overall led to an implant. Geurts and colleagues found that pain relief of at least 50 percent one week after test stimulation was associated with a higher chance of long-term success.

Hardware problems are the most common. In the Cleveland Clinic review of 707 cases by Mekhail and colleagues, hardware complications occurred in 38 percent, including lead migration in 22.6 percent, lead connection failure in 9.5 percent and lead breakage in 6 percent. Pain at the generator site occurred in 12 percent and infection in 4.5 percent. The review reported no permanent neurological deficits or deaths.

The reports cannot answer that question. An FDA adverse event report is unverified, may duplicate another report, and does not establish that the device caused the event. FDA does not publish the number of stimulators implanted, so the counts cannot be turned into a rate. The counts also cover every condition a stimulator is used for. Studies that follow a known group of patients give complication rates.

It depends on the facts, and a complication is not by itself a product defect. Revisions and removals are common with these devices: Hayek and colleagues reported revision and removal rates of 23.9 percent each at one academic center in 2015. An FDA recall or adverse event report does not prove that a particular device was defective. The guide to defective product claims explains the California rules and the federal limits on claims about implanted devices.

Guidelines place it after rehabilitation-based care, without calling it a last resort. The Royal College of Physicians' 2018 guideline says neuromodulation should be considered in patients who have not responded to integrated management that includes pain physiotherapy. The 2022 practical guidelines emphasize "shared decision making," with the risks, benefits and alternatives explained to the patient.

Sources

Every source below was opened and read for this page. The date is when it was last checked.

  1. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophyStudy · The New England Journal of Medicine (Kemler et al.), 2000 · checked
  2. Effect of spinal cord stimulation for chronic complex regional pain syndrome Type I: five-year final follow-up of patients in a randomized controlled trialStudy · Journal of Neurosurgery (Kemler et al.), 2008 · checked
  3. Economic evaluation of spinal cord stimulation for chronic reflex sympathetic dystrophyStudy · Neurology (Kemler and Furnee), 2002 · checked
  4. Spinal cord stimulation for complex regional pain syndrome type I: a prospective cohort study with long-term follow-upStudy · Neuromodulation (Geurts et al.), 2013 · checked
  5. Long-Term Outcome of Spinal Cord Stimulation in Complex Regional Pain SyndromeStudy · Neurosurgery (Hoikkanen et al.), 2021 · checked
  6. Retrospective review of 707 cases of spinal cord stimulation: indications and complicationsStudy · Pain Practice (Mekhail et al.), 2011 · checked
  7. Treatment-Limiting Complications of Percutaneous Spinal Cord Stimulator Implants: A Review of Eight Years of Experience From an Academic Center DatabaseStudy · Neuromodulation (Hayek et al.), 2015 · checked
  8. Long-term Outcomes in Use of Opioids, Nonpharmacologic Pain Interventions, and Total Costs of Spinal Cord Stimulators Compared With Conventional Medical Therapy for Chronic PainStudy · JAMA Neurology (Dhruva et al.), 2023 · checked
  9. A Comprehensive Outcome-Specific Review of the Use of Spinal Cord Stimulation for Complex Regional Pain SyndromeStudy · Pain Practice (Visnjevac et al.), 2017 · checked
  10. Interventions for treating pain and disability in adults with complex regional pain syndrome: an overview of systematic reviewsStudy · Cochrane Database of Systematic Reviews (Ferraro et al.), 2023 · checked
  11. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th EditionClinical guideline · Pain Medicine (Harden et al.), 2022 · checked
  12. Complex regional pain syndrome in adults: UK guidelines for diagnosis, referral and management in primary and secondary care, 2nd editionClinical guideline · Royal College of Physicians, 2018 · checked
  13. openFDA device adverse event and recall dataDataset · U.S. Food and Drug Administration · checked
  14. openFDA device adverse event reports for product codes LGW, GZB and PMP, with the openFDA disclaimerDataset · U.S. Food and Drug Administration · checked
  15. Closed Loop Spinal Cord Stimulation for Complex Regional Pain Syndrome (NCT06421350)Study · ClinicalTrials.gov (Scripps Health) · checked

Ask a lawyer about your CRPS case

Free case review. No fee unless we recover. A person from Wise Law reads every message.

What happened before the CRPS started? (optional)
Has a doctor diagnosed CRPS? (optional)
Or call (424) 235-7879

Submitting this form does not create an attorney-client relationship. An attorney-client relationship is formed only by a signed written fee agreement.

Text usCall